Surgical instruments and systems with multimodes of treatments and electrosurgical operation

Information

  • Patent Grant
  • 11389226
  • Patent Number
    11,389,226
  • Date Filed
    Friday, November 15, 2019
    4 years ago
  • Date Issued
    Tuesday, July 19, 2022
    a year ago
Abstract
In some embodiments, the inventive subject matter is directed to a multimode electrosurgical system having an electrosurgical instrument with a first electrode configuration that operates in a bipolar mode and second electrode configuration that operates in a monopolar mode. In other embodiments, the inventive subject matter is directed to an instrument and system that provide multiple modes of surgical and/or therapeutic treatments, at least one being an electrosurgical mode of treatment, the instrument including at least one active electrode on a working portion, and the working portion including or supporting at least one non-electrosurgical functional element, the instrument including at least one operational return electrode configuration of selectively variable surface area.
Description
BACKGROUND

In general the inventive subject matter is directed to a multimode surgical instrument that provides for (1) multiple modes of electrosurgical operation, and/or (2) multiple modes of surgical treatment. In certain embodiments, the inventive subject matter is directed to a multimode electrosurgical system with a set of return electrodes that can be variably engaged into operation to control a temperature at select electrodes in the set or at a target area adjacent the electrodes. The inventive subject matter, while adaptable to many surgical and therapeutic applications, is particularly suited for use in a system for liposuction. Accordingly, hereafter, a liposuction application will generally be used to illustrate the principles of the inventive subject matter and various possible embodiments thereunder.


In general, a liposuction procedure involves the insertion of a cannula into an area of a patient's body where subcutaneous fat tissue 1 is present. The cannula includes a valve assembly that couples to a suction source. The operator applies suction to the cannula or other hollow shaft to remove fatty tissue that is disrupted by a disrupter associated with the cannula. The disrupter may be a mechanical element, such as blade, or an energy emitter for disruption by targeted energy. For example, the tip of a cannula can be configured to scrape fat tissue. In other known systems, the cannula supports a laser device or ultrasonic device for targeting disruptive energy into tissue to fragment, melt, or vaporize tissue. One disadvantage of typical laser-liposuction devices is that the laser fiber is in placed in the main channel or lumen of the cannula so there cannot be simultaneous melting of fat by the laser and suction of the disrupted fatty materials.


Liposuction procedures may be dry field, wet field, or semi-wet field procedures. In a dry field, the cannula is inserted into the target area without the introduction of any fluid. In a wet field, a fluid is introduced into the target area through a lumen in the instrument. The introduced fluid may serve various functions. For example, it can be an irrigant that facilitates the suctioning of disrupted tissue. A semi-dry field is one where the target area is lightly irrigated. Accordingly, in a liposuction procedure the suctioned material may be primarily fatty material or a mixture of fatty material and an introduced fluid.


A significant disadvantage of all liposuction procedures is that when subcutaneous fat is removed from below the dermis, skin tension is reduced causing unsightly wrinkling, sagging or other surface irregularities in the skin. The degree of such irregularities may necessitate a surgeon to excise skin tissue and suture the exposed edges to tighten the skin surface. This is highly undesirably on several fronts, including the creation of scars and additional surgical risk.


Accordingly, there is a need for improved surgical and therapeutic instruments that simultaneously address multiple surgical and therapeutic needs. In the case of liposuction, there is a need for systems and instruments that not only meet the requirements for disruption and removal of fatty tissue, but also mitigate the cosmetic impact of liposuction on the skin's appearance.


SUMMARY

In some embodiments, the inventive subject matter is directed to a multimode electrosurgical system having an electrosurgical instrument with a first electrode configuration that operates in a bipolar mode and second electrode configuration that operates in a monopolar mode. In other embodiments, the inventive subject matter is directed to an instrument and system that provide multiple modes of surgical and/or therapeutic treatments, at least one being an electrosurgical mode of treatment, the instrument including at least one active electrode on a working portion, and the working portion including or supporting at least one non-electrosurgical functional element, the instrument including at least one operational return electrode configuration of selectively variable surface area.


The foregoing is not intended to be an exhaustive list of embodiments and features of the inventive subject matter. Persons skilled in the art are capable of appreciating other embodiments and features from the following detailed description in conjunction with the drawings. The following is a description of various inventive lines under the inventive subject matter. The appended claims, as originally filed in the underlying provisional application, and/or in this document, or as subsequently amended, are hereby incorporated into this summary section as if written directly in.





BRIEF DESCRIPTION OF THE DRAWINGS

The following figures show embodiments according to the inventive subject matter, unless noted as showing prior art. The Figures are not intended to be of scale.



FIG. 1 shows a schematic plan view of a system with a medical instrument with a working portion, which may have variable length, as indicted by broken lines.



FIG. 2 is a schematic, side-elevational view of a cross section of the instrument of FIG. 1, taken along line 2-2 in FIG. 1.;



FIG. 3A is a schematic view of a first mode of operation of the instrument of FIG. 1 in a target area of a patient's body. FIG. 3b is a schematic view of a second mode of operation of the instrument of FIG. 3A in the target area of the patient's body.



FIG. 4 is a block diagram of a set of components and associated channels for the components to intercouple with an ECU for purposes electrically activating or deactivating the components or communicating data signals.



FIG. 5 is a schematic, front-perspective view of one possible form for handle or hand piece used on the instrument of FIG. 1, with the handle or hand piece being shown in isolation from the working portion of the instrument.



FIG. 6 is graphing of theoretical impedance (x-axis)/power (y-axis) curves.



FIG. 7 is graphing of other theoretical impedance (x-axis)/power (y-axis) curves.





DETAILED DESCRIPTION

Persons skilled in the art will recognize that many modifications and variations are possible in the details, materials, and arrangements of the parts and actions which have been described and illustrated in order to explain the nature of the inventive subject matter, and that such modifications and variations do not depart from the spirit and scope of the teachings and claims contained therein.


Multiple Modes of Electrosurgical Operation


In some embodiments, the inventive subject matter is directed to a hybrid electrosurgical system and related instruments with a first electrode configuration that operates in a bipolar mode and second electrode configuration that operates in a monopolar mode. In certain embodiments, the inventive subject matter is directed to a multimode electrosurgical system with a set of return electrodes that can be variably engaged into operation to control a temperature at select electrodes in the set or at adjacent or nearby tissue.


In one possible embodiment, the instrument includes an active electrode, i.e., an electrode that is energizable and configured to deliver radio frequency (“RF”) energy to a target area in or on a patient's body. For example, the active electrode may be configured for vaporization, cutting, coagulating, ablating, or fulgurating of target tissue using parameters that are well known in the art. Electrode configurations for specific effects are known to persons skilled in the art. For example, electrodes with low surface area points of contact will be more suited for cutting of tissue, while broader surface areas are more suited for coagulating of tissue. The desired effect is also dependent on the frequency, power, waveform, and duty cycles of RF energy input though the electrode. The parameters for a desired effect are generally known to persons skilled in the art. In general, RF energy is supplied to the instrument by an electrosurgical generator that outputs a power profile to one or more active electrodes on an instrument. There are many commercially available sources of such generators, which are also known as Electrosurgical Control Units (“ECUs”). As used herein, ECU means the generator and associated control circuits. Control circuits need not be in the same housing as generator components and some may even reside remotely under separate housings or on the surgical instrument that couples to the generator components.


In addition to one or more active electrodes, electrosurgical instruments include at least one return electrode, and a current path is defined between the active and return electrode. In the case of a bipolar instrument, one or more return electrodes are disposed on the body of the instrument. The return electrode or electrodes provide a return path to the generator. In a monopolar instrument, the return electrode is not on the instrument but is remotely placed against a portion of the patient's body, typically against the buttocks. Such return electrodes may be referred to in the art as “patient pads.” They have sufficiently broad surface area so that current density is safely reduced to avoid burning the patient. One advantage of the inventive subject matter is that it provides multiple electrode configurations that allow for varying modalities of polarity: strictly bipolar operation, strictly monopolar operation, or alternating between bipolar and monopolar operation. As discussed in more detail below, the instrument shown in the Figures is configured for such varying modes of electrosurgical treatment.


Multiple Modes of Surgical Treatment


In some embodiments, the inventive subject matter generally relates to surgical and therapeutic systems and related instruments that provide multiple modes of treatments, at least one being an electrosurgical treatment. For example, the Figures show an instrument with the following modes: a first mode is used to perform liposuction on a patient; and a second mode is used to perform skin tightening in the same area as the liposuction. The second mode may be performed concurrently or separately from the liposuction mode.



FIG. 1 shows a system 9 that includes an instrument 10 and an associated electrosurgical control unit (“ECU”) 11 that supports electrosurgical modes of operation for the instrument. In the embodiment shown, the electrosurgical instrument 10 includes a working portion 12 that extends distally from a handle or handpiece 14, which may have controls for the user to activate or deactivate functions for the instrument. FIG. 2 shows a cross-section of the distal tip portion of the instrument taken along line 2-2 in FIG. 1. The working portion is typically elongate and is intended for use in or over a target area of a patient's body. The handle may also serve as a housing for components, e.g., for circuitry. In other instances, a graspable handle 14 is spaced from the housing of circuits. The distal end portion 16 of the working portion includes one or more electrodes, such as electrodes 18, 20a, 20b and/or 28. The system includes circuits or communication channels, e.g., C1-C4, for activity and controlling electrodes and other components on the instrument.


The ECU is configured to provide power to the instrument for energizing one or more active electrodes that may be disposed on the instrument. As described more fully below, the ECU can be configured to provide energy having a selected radio frequency and waveform.


Typically, a cable (not shown) extends between an electrical connector on the ECU control and an electrical connector on the electrosurgical instrument to electrically couple one or more conductive elements on or within the instrument to one or more corresponding conductive elements of the controller.


In certain embodiments, the inventive subject matter overcomes the disadvantages in the field of liposuction by providing for simultaneous disruption of fatty tissues and skin tightening in the target area of a patient. Heat induces collagen denaturation and collagen contraction, which in turn leads to new collagen formation in the dermis, which also results in epidermal tightening. While not intending to be bound by any theory of operation, under the inventive subject matter skin tightening is believed to be accomplished in the following manner. One or more return electrodes (e.g., 20a, 20b) of appropriate dimensions and shape are oriented toward the undersurface of the dermis where fatty tissue is being removed. (FIGS. 1-3b.) The return electrodes are conductive elements that conclude a current path (e.g., 22a, 22b) with the active electrode (e.g., 18). Heat is generated along the path, as resistive heating from the current. (FIGS. 3a-3b.) Accordingly, non-ablative, thermal energy emanates from a current path. The heat transfers to the tissue adjacent the current path and/or the return electrodes.


In the example of the Figures, the active electrode 18 is configured as a ring disposed about the distal opening 24 of working portion 12, which in this case is a cannula with one of more lumens 25. The inventive subject matter is not limited to ring-shaped active electrodes. Any other shape that achieves a desired effect can be used. For example, the active electrode at the distal end of the instrument 10 could have a bull-nose like configuration.


Looking at instrument 10, a pair of return electrodes is disposed in line with the longitudinal axis of the cannula, and on the outer surface of the cannula. The instrument or associated ECU is configured with circuitry to allow for manual or automatic switching on and off of the return electrodes according to predefined parameters such as temperature or duty cycles. The ECU also includes similar manual or automatic switching circuitry for switching on and off a patient pad coupled to the system.


The cannula has side walls defining at least one lumen (e.g., 25) for transporting materials or things from or to the target area of a patient. The cannula shown in the Figures has a circular cross-section, but the cross-section can vary. For example, it can be an oval, square, hexagonal, a complex curve, or any other shape that defines a lumen or serves an intended purpose. The working portion may also have multiple lumens of desired cross-sections that run in parallel fashion along the working portion. For example, a first lumen could be connected to a suction source for applying suction at a target site and removing loose materials. That same lumen could optionally be used for other purposes. For example, it could serve as the lumen for introduction of a fluid to the target site. A second lumen could be used to introduce another instrument or tool, such as a laser fiber, that delivers energy to the target site or to introduce a fluid or other material to the target site. A second or third lumen could be used to provide a channel for introducing an endoscope for viewing a target area. The distal end portion 16 of the instrument could also include a built-in image sensor for imaging at a target site, and optionally a light source, both of which are well-known features in the field of endoscopy and minimally invasive surgery.


Although the working portion for instrument 10 shown in the Figures has a straight shaft, the inventive subject matter is not limited to that configuration. For example, the distal portion 16 of the shaft could be angled off of a proximal, straight portion, i.e., a jog off the major longitudinal axis of the instrument. Such angling could allow the return electrodes to make better contact with tissue when the targeted tissue 1 is parallel to the shaft. Alternatively, the return electrodes could be placed on the angled portion when the targeted tissue is transverse to the major, longitudinal axis of the working portion.


In some embodiments suitable for skin tightening, particularly skin tightening in connection with a liposuction procedure, a cannula of about 4 mm outer diameter is suitable. The return electrode configuration on such a cannula may be about 7 mm wide and about 23 mm long (or other dimensions of similar surface area), as a single return electrode unit or aggregation of smaller return electrode units (e.g., return electrodes 20a and 20b). The return electrodes may be made of a suitable conductive material such as aluminum, copper, silver, or alloys of conductive materials. The return electrodes may be disposed on the cannula as a thin foil or sheet of conductive material. They could also be formed as a coating on the surface of the cannula by other means. For example, a vapor deposition or metal printing technique could be used to metallize an area of a cannula. Because cannulas and other working portion configurations are typically made of a conductive material, e.g., stainless steel, a non-conductive layer 26 of material will be disposed between the main body (or other conductive substrate) of the cannula and the return electrodes. The return electrodes may have varying shape and surface area, but for use in skin tightening they would at least be configured for a non-ablative, thermal effect on tissue.


In operation, a current path is defined by (1) one or more active electrodes (e.g., 18), which are used to disrupt fatty tissue, disposed at the distal end portion 16 of the cannula 12; and (2) one or more operational return electrode or electrodes (e.g., 20a and 20b) that are spaced from the active electrode(s) and disposed on the outer surface of the cannula. The current flow occurs along the defined path(s) 22a and/or 22b when the instrument is operated in bipolar mode. A remote electrosurgical generator supplies the power to drive the current. As the instrument is steadily used in a procedure, the area of the current path leading to the operational return electrodes will heat. To control temperature so that that the dermis 2, which is the layer directly above subcutaneous fat, will heat within selected temperature range, each active electrode may be placed in a switchable circuit with a monopolar operating mode of the generator and one or more patient pads 28 on the exterior surface of the patient's body.


To effect skin tightening, the dermis is maintained between a target temperature range of from 39 degrees or thereabout C to 55 degrees C. or thereabout, with a temperature of 42 degree or thereabout being suitable. Tissue temperature may be monitored directly or by approximation by monitoring temperatures at the return electrode adjacent the treated tissue.


Referring to FIG. 4, the system may be configured with upper and lower limits for switching the return electrodes from bipolar mode to monopolar mode. In bipolar mode, the functioning return electrodes are the onboard return electrodes (e.g., 20a and/or 20b) on the surface of the cannula. But in monopolar mode, the onboard return electrodes are deactivated from being in circuit with the generator and at least one patient pad 28 in contact with a patient is activated into a circuit in communication with the generator. Relative to the return electrodes on the cannula, the broader surface area of the patient pad provides substantially reduced current density and consequently relatively little heating. While in the monopolar operational mode, the target tissue 1 adjacent the return electrodes 20a, 20b on the cannula can cool back into the defined temperature range for skin tightening. In some embodiments, the patient pad may be maintained on the outside of the epidermis at the area of dermis being treated, or thereabout, thereby providing a more direct and efficient current path.


The inventive subject matter contemplates the use of a single patient pad 28 or multiple, spaced-apart patient pads, as seen in FIG. 4. Typically a monopolar patient pad is an electrode of about 4 inches by 5 inches (or different dimensions or shapes but similar surface area). If multiple pads are used, they can be selectively activated and deactivated. For example, if a first pad is heating beyond predefined limits, a second pad could be activated, with or without deactivating the first pad.


In certain embodiments, the inventive subject matter contemplates a system with one or more return pads 28. In general, the ratio of the area of the return pad relative to the area of the active portion (active end-effector) determines the relative proportion of energy that is deposited at each location. The larger the ratio, the greater the percentage of heat generated in the tissue at the smaller terminus. To control the amount of heat generated in the dermal layer, while at the same time assuring that there is sufficient heat to melt or otherwise disrupt the fat at the end effector, the system switches between the various return pads.


One possibility envisioned is for the return pad to be coupled to the hand of the physician operating instrument 10. During the course of the lipo-suction procedure, it is not unusual for the physician to apply external pressure to the patient over the area being evacuated. By having one return pad coupled to the physician's hand (palm and/or fingers), the return pad is thus always maintained in an ideal location relative to the treatment area. Accordingly, the inventive subject matter contemplates systems and methods related to the coupling of a return pad on the user's hand. A return pad could, for example, be in glove form or have finger straps or bands to enable the pad to secure to the user's hand or fingers.


In other embodiments, the inventive subject matter contemplates components and methods for control over impedance during a procedure. For example, one possibility with having the return electrode disposed on either the shaft of the liposuction probe or to the hand of the physician is that contact between the patient and the return electrode can be intermittent. Intermittent contact results in a loss of energy flow to the active electrode and may also generate unwanted sparking at the return electrode. A solution to this is to have at least one return electrode designated for constant service during a procedure and one or more other return electrodes, such as those on the cannula or coupled to a user's hand, that can have varying degrees of contact, from no contact to full contact with treatment areas. The return electrode designated for constant service can control the flow of energy between the various pads so as to (1) maintain both a constant flow of energy and (2) help reduce or eliminate unwanted sparking or deactivation of the active electrode.


The parameters for design and operation of skin tightening systems are found in various patents under a common assignment to the assignee of this application. These include U.S. Pat. Nos. 8,359,104, 8,321,031, and 8,317,782, the contents of which are incorporated herein by reference in their entireties. However, these devices are configured with an active electrode for direct application of RF energy to the epidermal side of the skin. In contrast, the embodiments contemplated herein use the heat generated off the current path to the return electrode, not the active electrode, to apply thermal energy to the dermis to heat it to skin-tightening temperatures. The active electrode is in a cutting mode to disrupt target tissue and is in a surgical mode of electrosurgical treatment; it is not in an aesthetic mode of electrosurgical treatment (see discussion below). Nonetheless, in some possible embodiments, a liposuction instrument could be configured with an active electrode for application of RF energy to the dermis using an aesthetic or similar therapeutic, non-surgical mode of treatment.


To measure or estimate temperature at selected target tissue and/or on instrument components, temperature sensors (e.g., 30a, 30b) may be optionally incorporated into the instrument 10, as seen in FIGS. 1-2, for example. For example, one or more thermistors may be incorporated into the instrument. As seen in the Figures, separately readable thermistors 30a, 30b are disposed adjacent to each return electrode 20a, 20b to measure the temperature in the proximity of the electrodes that results from heat transfer. In this example, the thermistors are integrated between the lower surface of the return electrodes 20a, 20b and the top surface of the layer 26 of insulating material on which the return electrodes are disposed. An infrared sensor may also be disposed on or off instrument 10 and associated with the return electrodes or otherwise to monitor temperature at the target site.



FIGS. 3A and 3B illustrate a distal working portion 16 of a cannula 12 with two return electrodes 20a, 20b. The distal portion 16 is at a subcutaneous layer of fatty tissue 1, which is the target for liposuction. In a first mode of operation (FIG. 3A), where at t (time)=1, only a first return electrode 20a is in operation and working within a temperature range for skin tightening. The globular area represents fatty tissue in front of the distal tip portion 16 of the instrument. An active electrode 18 at the tip is energized and disrupting that tissue. Above and parallel to the distal working portion is the underside of the dermis 2. The current path 22a is indicated by the arcing lines run from the distal tip to a first, distal return electrode 20a. This represents a current path from the active electrode 18 to the first return electrode 20a. A second, proximal return electrode 20b is deactivated and not in the current path at t=1. In a second mode of operation (FIG. 3B), where t=2, a temperature that exceeds a defined limit has been sensed for the targeted dermis. When this occurs, the second return electrode 20b is activated into operation. This is indicated by a second set of arcing lines for a current path 22b, which extends beyond the first current path 22a all the way to the second return electrode 20b. With the second return electrode 20b activated into operation along with the first electrode 20a, the aggregate surface area of return electrodes has increased and the overall temperature of the area by the return electrodes can be maintained under the defined limit for a given power profile.


Modulation of tissue temperature can be achieved by alternating between different return electrodes in a set of return electrodes included in a system, e.g., the electrodes disposed on a working portion of an instrument and/or a patient pad. Each return electrode may be separately addressable and switchable. This allows for parallel or sequential use of the return electrodes. It also allows for variable overall current densities based on the aggregate surface area of the return electrodes in service. For example, if a first return electrode is too hot, a second one can be activated into service to increase the aggregate surface area and thereby decrease overall heating. Similarly, by providing an array of two or more return electrodes on the surface of the cannula, some return electrodes may always be kept in service to heat tissue for skin tightening while others are in a cooling phase.


In the case of a liposuction instrument with return electrodes for skin tightening, temperature readings could be taken at the underside of the dermis or at the epidermis, or at both locations to monitor for temperatures sufficient to denature collagen and to help avoid overheating of the epidermis or other tissue. Accordingly, the inventive subject matter is directed to systems and methods for controlling the temperature of tissue in contact with a defined set of return electrodes by varying the aggregate surface area of all return electrodes (whether in a bipolar or monopolar circuit) that are in a current path with an active electrode.


As can be seen in the Figures, the instrument 10 optionally may include one or more apertures (e.g., 32a, 32b, 32c) about the return electrodes 20a, 20b that are in communication with channels (e.g., 17) in the instrument that can couple with a suction source (not shown). The application of suction will cause the instrument to draw up against adjacent tissue to bring the return electrode in contact or closer contact with the tissue that is targeted for heating and tightening. In the embodiment of FIG. 1, the apertures 32a, 32b, 32c are in line with the return electrodes 20a, 20b. In addition to, or instead of, such an arrangement, the apertures could be spaced along one or both sides of the electrodes in a generally parallel fashion.


In some embodiments, the instrument is configured for establishing orientation with target tissue so that return electrodes may be positioned adjacent to target tissue. For example, the side 34 of the shaft or handle 14 in line with the return electrodes 20a, 20b could have a different shape or dimension than other sides. For example, cannula 12 is connected to a handle 14 having a generally triangular cross section (FIGS. 1 and 5). One side 34 of the handle, which corresponds to the side on the cannula where the return electrodes are disposed, has a relatively broad, planar surface. The other two surfaces 35 are not planar but arcuate. In addition to geometrical configurations that differentiate a return-electrode side or other defined side from other sides, other ways of determining orientation are contemplated. For example, orientation could be determined using an imaging sensor that allows for viewing from the return electrode side of the instrument or inertial sensors that follow motion. Another approach is color coding or placing of any other graphical indicator (e.g., letters, words, numbers, symbols) or other visible indicator (e.g., light emitters) on a side of the handle or working portion that marks that side as corresponding to a predefined area on the instrument. This approach is not limited to use with return electrodes but also can be used to indicate the orientation of other functional features in the instrument. If there are multiple placements of return electrodes or other features spaced about the circumference, the handle or other portion of the instrument that extends from a target can be coded with corresponding indicia of orientation.


In certain embodiments, the inventive subject matter is directed to systems and methods for modulating the form of energy delivered through one or more active electrodes associated with an instrument and/or modulating the aggregate surface area of operational return electrodes (bipolar and monopolar). These can be achieved through a set of computer executable instructions stored in volatile or non-volatile memory associated with the instrument. The instructions can be executed by a computer processor associated with an ECU 11 that is coupled to the instrument. Looking at FIGS. 6 and 7, first and second theoretical graphs of Power (Y-axis)/Impedance (X-axis) are shown. Higher powers means the active electrode will be more effective at delivering energy to tissue for an intended surgical effect, such as cutting or coagulating. In FIG. 6, curve I shows how power varies with impedance in a relative broad bell-shaped curve. This curve indicates how power would vary for some common ESUs. Curve II represents a power profile for a more specialized ESU. This represents a profile where peak power is in a narrow band. Power quickly falls off as impedance increases or decreases. This profile could be used where the peak power corresponds to tissue type having an inherent impedance under the peak. This profile therefore allows for a self-limiting effect on tissue. For example, it could be used to coagulate bloody, ulcerous tissue. As the tissue is coagulated, its impedance quickly increases and power drops, which prevents damage to tissue surrounding the target tissue.


Turning to FIG. 7, a first curve I represents a sometimes desirable flat power curve for working with a broad range of tissues where defined power output can be maintained across a range of impedances corresponding to the varying impedances of different kinds of tissues. A second curve II represents a selected peaking of power at a defined impedance. In this example, the peak power is at relatively high impedance generally corresponding to the impedance of fatty tissue, such as is encountered during liposuction. This allows the system to selectively disrupt fatty tissue relative to other kinds of tissue. In other words, there is a high coupling efficiency between the power profile and the target tissue. Accordingly, the selectivity allows for less power delivery to lower impedance, non-target tissues, such as veins, arteries and muscle. Such tissues are therefore better protected from accidental trauma.


Various ECU systems may be used to create desired power profiles. For example, some known ECUs provide three output terminals, with one of the terminals being an energizable terminal for conveying energy, e.g., RF energy, to an energizable element of a handpiece. Such an ECU is usually configured to energize the energizable terminal when a circuit between the two remaining output terminals is completed, as through the closing of a user-actuated switch or an automatically programmed switch. In some embodiments discussed herein, a programmed switch operates depending on predefined temperature limits for the points on the instrument and/or patient target area.


Known ECUs include those manufactured by Ellman International, such as those under the brand SURIGTRON and described in U.S. Pat. No. 6,652,514, the contents of which are incorporated herein by reference in their entirety. The SURGITRON provides a three-wire output connector for powering and controlling electrosurgical handpieces. Conventional ECUs can generate, for example, one or more radio-frequency (RF) modulated waveforms, e.g., at a frequency of about 4 megahertz (MHz), which can be delivered to a target site by way of an electrosurgical handpiece having an energizable electrode defining an active surface. ECUs configured for both monopolar and bipolar operations have been developed by the assignee of this application and are disclosed in U.S. Pat. No. 7,479,140, the contents of which are incorporated herein by reference in their entirety,


In some cases, the active surface of an electrosurgical system can be configured for ablative and/or non-ablative electrosurgery. As used herein, an ablative procedure is one where the electrode and power settings result in cutting, coagulation, vaporization or other such traumatic disruption to the integrity of treated tissue, and a non-ablative procedure is one where such cutting, coagulation, vaporization or other such traumatic disruption to the integrity of treated tissue does not result. An electrosurgical instrument can be configured provide a given combination of operating parameters suitable for achieving a desired therapeutic outcome based on a user's selection of therapeutic outcome and, for example, configuration of energizable electrode. Some electrosurgical instruments are configured to recognize a configuration or type of energizable electrode automatically.


A typical instrument configured for use in the surgical market segment delivers a peak output power of about 300 watts RMS (e.g., between about 290 Watts RMS and about 310 Watts RMS) in a cutting mode, and a lower peak power corresponding to each of a coagulate and fulgurate modes. A typical instrument configured for use in the aesthetic market segment delivers a peak output power of about 400 watts RMS (e.g., between about 385 Watts RMS and about 415 Watts RMS) in an “aesthetic mode” (e.g., skin tightening), about 300 Watts RMS in a surgical cutting mode and a lower peak power corresponding to each of a coagulate and fulgurate mode.


As used herein an “electrosurgical treatment mode” means a distinct configuration of an electrosurgical instrument corresponding to a distinct perceived result arising from a given user input. Each distinct configuration can correspond to a physical configuration, a software configuration, a firmware configuration, or a combination thereof.


In some respects, general functional characteristics of disclosed instruments can best be understood in the context of “electrosurgical treatment modes”. In general, an electrosurgical mode is defined by a waveform comprising a given frequency, duty cycle, and amplitude (e.g., a maximum power output). Several representative examples of “modes” corresponding to respective therapeutic outcomes follow:

    • Cut—4 MHz and/or 400 kHz frequency, 90%-100% duty cycle sine wave at 300 watts RMS max power
    • Blend 1—4 MHz and/or 400 kHz frequency, 25%-75% duty cycle sine wave at 250 watts RMS max power
    • Coag/Hemostasis—4 MHz and/or 400 KHz frequency, 10%-40% duty cycle sine wave at 200 watts RMS max power
    • Fulgurate—4 MHz and/or 400 kHz frequency, very low duty cycle sine wave at 150 watts RMS max power
    • Aesthetic Mode I—4 MHz and/or 400 kHz, 90%-100% duty cycle sine wave at 300 watts RMS max power
    • Aesthetic Mode II—4 MHz and/or 400 kHz mixed frequency 90%-100% duty cycle sine wave at 300 watts RMS max power
    • Bipolar—4 Mhz and/or 400 kHz, 1.7 MHz, and/or 400 kHz frequency undetermined duty cycle sine wave at 100 watts RMS max power


Each of the modes listed above except the Aesthetic Modes I & II is intended primarily for use in a surgical procedure. Aesthetic Modes I & II are modes intended primarily for use in aesthetic therapies. U.S. patent application Ser. No. 11/897,035, which is owned by the assignee of this patent application and is incorporated herein in its entirety, discloses an electrosurgical instrument configured to generate three carrier frequencies, four operating modes represented by different electrical modulation waveforms, and to combine each of the three carrier frequencies with any of the electrical modulation waveforms representing the different operating modes to form a unique set of electrosurgical currents, and to deliver such electrosurgical currents to either of a connected monopolar or bipolar handpiece or an instrument configured to offer both modes of operation.


As used herein “electrosurgical treatment mode” means a distinct configuration of an electrosurgical instrument corresponding to a distinct perceived result arising from a given user input. Each distinct configuration can correspond to a physical configuration, a software configuration, a firmware configuration, or a combination thereof.


U.S. patent application Ser. No. 11/897,035 teaches that operational modes include monopolar and/or bipolar activation, and a user selection of carrier frequency and modulating waveforms representing one of the four operating modes. Generally, the modulation frequencies will vary from 0 Hz to 35 KHz. Specifically, the four operating electrosurgical modes are represented by cutting: CW output with maximum (or 90%-100%) average power obtained with full-wave rectified and filtered carrier waveforms; cutting/coagulation: approximately 25%-75% average power output achieved with amplitude modulated or pulsed sine wave “with a pulse” frequency on the order of 100 to 5000 cps; hemostasis: approximately 10%-40% average power output achieved with amplitude modulated or pulsed sine wave with a “pulse” frequency on the order of 100 to 5000 cps with a lower duty cycle than seen on the cutting/coagulation mode; fulgurate (or Spark-Gap Wave): approximately 20% average power output achieved with very short repeating bursts of high voltage energy, with on the order of 100 to 5000 cps. The percentages given are with respect to the maximum value.


The various combinations of carrier frequency and modulation combined with the choice of handpiece selected by the user/surgeon produces a remarkable number of active electrosurgical currents with a wide variety of tissue effects. Three different carriers each with four different modulations applicable to tissue via either of two different handpieces provides a total of 12 different electrosurgical currents via the two handpieces and provides, in essence, at selected power levels varied levels of coagulation and cutting. This includes not only the usual high power tissue cutting currents, as well as low power bleeder coagulation currents but also more modest tissue effects with controllable lateral heat spread better suited around critical anatomical parts for hemostasis, as well as lower frequency currents for application to liquid-heavy surgical procedures. While, generally speaking, the monopolar operation is preferred for smooth cutting and combined cutting and coagulation, whereas bipolar operation concentrates the electrosurgical currents between the active and return electrodes, and is thus preferred for local hemostasis with lower power, many surgical situations may arise where it is preferred that higher power electrosurgical currents are applied with the bipolar operation and lower power electrosurgical currents with the monopolar operation.


In some embodiments, the first carrier frequency is in the range of about 3.8-4.0 MHz or thereabout, the second carrier frequency is in the range of about 1.7-2.0 MHz or thereabout, and the third carrier frequency is in the range of about 400-600 KHz or thereabout. In some embodiments, the values are 4 MHz or thereabout, 1.71 MHz or thereabout, and 500 KHz or thereabout.


In some embodiments, the first, second and third carrier frequencies are derived by division by 2 upon selection from RF carrier generators at double the desired frequencies which simplifies the RF generator selection circuitry.


The foregoing are non-limiting, representative RF and other power profile parameters. Other such parameters can be employed depending on application needs.


The names and/or specifications for the individual modes described herein are merely exemplary in nature and can vary from those presented herein. For example, some instruments described herein are software or firmware programmable. Such instruments allow a given hardware configuration to be tailored to specific market segments, or end uses. For example, a user, a manufacturer, a distributor, a reseller, etc., may define particular waveforms, or modes, in correspondence to a selected therapeutic outcome. As but one example, a given waveform might be relatively more suitable for cutting a first type of tissue than another waveform, whereas the other waveform might be relatively more suitable for cutting a second type of tissue. Instruments as disclosed herein can be programmed with one or the other waveforms to correspond to an end-user's preferred use (e.g., one end-user might be more likely to cut the first type of tissue, so an instrument provided to that end user can be programmed to provide the corresponding more effective waveform when a “cut” function is selected).


Such market-segment differentiation using the same base hardware can permit a manufacturer to enjoy economies of scale during production, while also being able to supply each distinct market segment with suitable, competitive product.


As used herein, “and/or” means “and” or “or”, as well as “and” and “or.” Moreover, any and all patent and non-patent literature cited herein is hereby incorporated by references in its entirety for all purposes.


The principles described above in connection with any particular example can be combined with the principles described in connection with any one or more of the other examples. Accordingly, this detailed description shall not be construed in a limiting sense, and following a review of this disclosure, those of ordinary skill in the art will appreciate the wide variety of systems that can be devised using the various concepts described herein. Moreover, those of ordinary skill in the art will appreciate that the exemplary embodiments disclosed herein can be adapted to various configurations without departing from the disclosed principles.


The previous description of embodiments is provided to enable any person skilled in the art to make or use the disclosed innovations. Various modifications to those embodiments will be readily apparent to those skilled in the art from the teachings herein, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of this disclosure. Thus, the claimed inventions are not intended to be limited to the embodiments shown herein, but are to be accorded the full scope consistent with the language of the claims. In the claims reference to an element in the singular, such as by use of the article “a” or “an” is not intended to mean “one and only one” unless specifically so stated, but rather “one or more”.


All structural and functional equivalents to the elements of the various embodiments described throughout the disclosure that are known or later come to be known to those of ordinary skill in the art are intended to be encompassed by the features described and claimed herein. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed as “a means plus function” claim under US patent law, unless the element is expressly recited using the phrase “means for” or “step for”.


The inventor reserves all rights to the subject matter disclosed herein, including the right to claim all that comes within the scope and spirit of the following claims:

Claims
  • 1. An electrosurgical system, comprising: a working portion with an electrode configuration that operates in a bipolar mode and has an active electrode and a plurality of return electrodes, each return electrode being separately addressable from each other return electrode and the active electrode, wherein at least one of the separately addressable return electrodes is continuously operable to maintain an activated current path with the active electrode, and at least one other separately addressable return electrode is selectively activatable to provide continuous control of an aggregate surface area of the return electrodes in service and thereby to provide continuous control of a current density applied in or over a target area;the electrosurgical system configured to deliver a peak power at a defined impedance corresponding to an impedance value of fatty tissue; andwherein the power decreases as impedance either increases or decreases relative to the defined impedance, thereby providing a self-limiting effect on an adjacent tissue type different than fat tissue.
  • 2. The electrosurgical system of claim 1 wherein the plurality of return electrodes comprises a set of two or more return electrodes that can be selectively engaged into operation to control a temperature at one or more electrodes in the set of two or more return electrodes.
  • 3. The electrosurgical system of claim 2 wherein each of at least two return electrodes in the set of two or more return electrodes can be separately engaged into operation relative to at least one other return electrode in the set.
  • 4. The electrosurgical system of claim 2 wherein one or more temperature sensors is associated with each return electrode.
  • 5. The electrosurgical system of claim 4 wherein each separately addressable return electrode is associated with a separately readable temperature sensor.
  • 6. The electrosurgical system of claim 5 further comprising circuitry for switching at least one electrode automatically into or out of service in correspondence with a plurality of predefined parameters, at least one of the parameters being a temperature reading in proximity to at least one return electrode.
  • 7. The electrosurgical system of claim 2, wherein the electrode configuration comprises a first electrode configuration, the system further comprising a second electrode configuration that operates in a monopolar mode, a return electrode that is separate from the instrument and usable in the monopolar mode of operation.
  • 8. The electrosurgical system of claim 1 further comprising an ECU and a corresponding controller, wherein each electrode in the electrode configuration is in communication with the controller.
  • 9. The electrosurgical system of claim 1 further comprising a shaft defining a lumen and a valve assembly couplable to a suction source, which becomes in fluid communication with the lumen.
  • 10. The electrosurgical system of claim 1 wherein the system is configured to activate or deactivate one or more return electrodes depending on readings from one or more temperature sensors associated with the one or more return electrodes or the target area.
  • 11. The electrosurgical system of claim 1 wherein the system further comprises a processor and a storage medium with stored executable instructions that, when executed, cause the processor to control one or more of a frequency, a power, a waveform, and a duty cycle of RF energy input though the active electrode in correspondence with a desired electrosurgical operation mode.
  • 12. The electrosurgical system of claim 11 wherein the system is configured to modulate heating at return electrodes by modulating duty cycles for the operation of the electrodes, the modulation being based on readings from one or more temperature sensors in the system.
  • 13. The electrosurgical system of claim 1 wherein the system is configured to activate one or more return electrodes into service as a temperature limit is sensed by one or more temperature sensors.
  • 14. The multimode electrosurgical system of claim 1, wherein the instrument includes a second working portion comprising one or more of the plurality of return electrodes, the system being configured so that the active electrode provides an ablative thermal treatment effect at a first target area and one or more of the return electrodes are controllable to provide a non-ablative thermal effect at a second target area spaced apart from the first target area while the active electrode is at the first target area.
  • 15. The multimode electrosurgical system of claim 14, wherein the system is configured to activate or deactivate one or more return electrodes into or out of service as a temperature limit is sensed by one or temperature sensors disposed on the instrument so as to monitor the temperatures at the second target area.
  • 16. The multimode electrosurgical system of claim 15, wherein the system is configured to selectively disrupt fatty tissue relative to other kinds of tissue through the active electrode when the instrument is in fatty tissue at the first target area and to provide the non-ablative thermal effect on tissue at the second target area.
  • 17. The multimode electrosurgical system of claim 1, wherein the system is configured with selectivity that allows for less power delivery to lower impedance, non-target, non-fatty tissues, namely veins and arteries, and wherein a second mode of the electrosurgical system is configured to concurrently maintain a layer of tissue adjacent the fatty tissue at a selected temperature while effecting disruption of the fatty tissue.
  • 18. The multimode electrosurgical system of claim 1, wherein at least one of the return electrodes has a surface operably orientable towards a tissue type different than fatty tissue when the active electrode is operably oriented toward a fatty tissue layer.
  • 19. The multimode electrosurgical system of claim 18, wherein the working portion comprises a cannula defining at least one lumen, the active electrode being disposed at the distal end of the cannula and the return electrodes being spaced from the active electrode and disposed on the surface of the cannula, in line with its longitudinal axis, the arrangement of active and return electrodes defining a current path for the non-ablative heating of the different tissue adjacent the fatty tissue while the active electrode is operated in an ablative mode.
  • 20. The multimode electrosurgical system of claim 19, wherein the active electrode comprises a ring-shaped electrode disposed on the distal tip of the cannula.
  • 21. A multimode electrosurgical system, comprising an electrosurgical instrument, the instrument having a working portion with an electrode configuration that operates in a bipolar mode and has an active electrode and a plurality of return electrodes, each return electrode being separately addressable, wherein at least one of the separately addressable return electrodes is continuously operable to maintain an activated current path with the active electrode and at least one other separately addressable return electrode is selectively activatable to provide continuous control of an aggregate surface area of the return electrodes in service and thereby to provide continuous control of a current density applied to a target area, the electrosurgical system configured to deliver a peak power at a defined impedance corresponding to an impedance value of fatty tissue contained in the target area, and wherein the power decreases as impedance either increases or decreases relative to the defined impedance, thereby providing a self-limiting effect on a tissue type different than fatty tissue wherein the electrode configuration comprises a first electrode configuration, the system further comprising a second electrode configuration that operates in a monopolar mode, a return electrode separate from the instrument and usable in the monopolar mode of operation against a patient's body.
  • 22. The system according to claim 21, further comprising circuitry configured to selectively activate the return electrode operable in the monopolar mode as a temperature limit is sensed by one or more temperature sensors.
  • 23. A method of liposuction and skin tightening comprising inserting a working portion of an instrument in or over a target area comprising subdermal fatty tissue, the working portion having an active electrode and at least two return electrodes, at least one of the return electrodes having a surface being oriented towards a dermal layer when the active electrode is oriented toward the fatty tissue, wherein at least one of the return electrodes is configured to be continuously operable to maintain an activated current path with the active electrode, and at least one other return electrode is configured to selectively activate and deactivate to provide continuous control of an aggregate surface area of the return electrodes, the return electrodes being selectively activatable from each other return electrode and the active electrode; energizing the active electrode with a peak power at a defined impedance corresponding to an impedance value of fatty tissue contained in the subdermal fatty tissue adjacent the dermal layer, wherein the power decreases from the peak power as impedance either increases or decreases relative to the defined impedance, thereby providing a self-limiting effect on a tissue type different than fatty tissue; and controlling the temperature at epidermal tissue of the dermal layer within a range to effect skin tightening by selectively activating or deactivating the at least one other return electrode to control the aggregate surface area of the return electrodes and thereby to control a current density applied to the target area.
  • 24. A method of disrupting fatty tissue in a target area of a patient, the method comprising: applying a working portion of an instrument in or over the target area, the working portion having an active electrode and a plurality of return electrodes that are capable of electrical contact with the target area, each return electrode being separately addressable from each other return electrode and the active electrode;energizing the active electrode with a peak power at a defined impedance corresponding to an impedance value of fatty tissue in the target area, wherein the power decreases from the peak power as impedance either increases or decreases relative to the defined impedance, thereby providing a self-limiting effect on a tissue type different than fatty tissue;monitoring a tissue temperature in the target area; andmaintaining the tissue temperature within a selected temperature range by selectively activating and/or deactivating any one or more of the return electrodes to vary an aggregate surface area of all return electrodes in a current path with the active electrode in response to the tissue temperature in the target area falling below a selected upper threshold temperature or exceeding a selected upper temperature threshold, respectively.
  • 25. The method of claim 24 further comprising controlling one or more of a frequency, a power, a waveform, and a duty cycle of RF energy input though the active electrode in correspondence with a desired electrosurgical operation mode.
  • 26. The method of claim 25 further comprising modulating heating at return electrodes by modulating duty cycles for the operation of the electrodes, the modulation being based on readings from one or more temperature sensors associated with the instrument.
  • 27. A method of disrupting fatty tissue in a target area of a patient, comprising: applying a working portion of an instrument in or over the target area comprising the patient's dermal layer, the working portion having an active electrode, a constant-service return electrode, and one or more return electrodes, each return electrode being separately addressable from each other return electrode and the active electrode, each of the active and return electrodes being capable of electrical contact with the target area;energizing the active electrode with a peak power at a defined impedance corresponding to an impedance value of fatty tissue at the target area, wherein the power decreases from the peak power as impedance either increases or decreases relative to the defined impedance, thereby providing a self-limiting effect on a tissue type different than fatty tissue;monitoring a tissue temperature in the target area; andmaintaining the tissue temperature within a selected temperature range by selectively activating and/or deactivating any one or more of the separately addressable return electrodes to vary an aggregate surface area of all return electrodes in a current path with the active electrode in response to the tissue temperature in the target area falling below a selected upper threshold temperature or exceeding a selected upper temperature threshold, respectively.
  • 28. The method of claim 27 further comprising controlling one or more of a frequency, a power, a waveform, and a duty cycle of RF energy input though the active electrode in correspondence with a desired electrosurgical operation mode.
  • 29. The method of claim 28 further comprising modulating heating at return electrodes by modulating duty cycles for the operation of the electrodes, the modulation being based on readings from one or more temperature sensors associated with the instrument.
RELATED APPLICATIONS

This application claims the benefit of and priority to U.S. patent application Ser. No. 14/214,627, filed on Mar. 14, 2014, which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/794,732, filed Mar. 15, 2013, the contents of which are hereby incorporated by reference as if recited in full herein for all purposes.

US Referenced Citations (535)
Number Name Date Kind
236203 Campbell Jan 1881 A
1881250 Tomlinson Oct 1932 A
1916722 Ende Jul 1933 A
1942543 Forman Jan 1934 A
1943543 McFadden Jan 1934 A
1945327 Morse Jan 1934 A
1983669 Kimble Dec 1934 A
2102270 Hyams Dec 1937 A
2888928 Seiger Jun 1959 A
3058470 Seeliger et al. Oct 1962 A
3532095 Miller et al. Oct 1970 A
3730188 Ellman May 1973 A
3799168 Peters Mar 1974 A
3825004 Durden Jul 1974 A
3825044 Lidikay et al. Jul 1974 A
3858586 Lessen Jan 1975 A
3879947 Gaiser Apr 1975 A
3916909 Kletschka et al. Nov 1975 A
3920022 Pastor Nov 1975 A
D246053 Staub et al. Oct 1977 S
4051855 Schneiderman Oct 1977 A
4071028 Perkins Jan 1978 A
4103688 Edwards Aug 1978 A
4108182 Hartman et al. Aug 1978 A
4123673 Gonser Oct 1978 A
4137919 Farin et al. Feb 1979 A
4148321 Wyss Apr 1979 A
4148324 Muller et al. Apr 1979 A
4171700 Farin Oct 1979 A
4188927 Harris Feb 1980 A
4221222 Detsch Sep 1980 A
4185927 Uttech Oct 1980 A
4246902 Martinez Jan 1981 A
4271891 Pommier Jan 1981 A
4269174 Adair May 1981 A
4271837 Aesculap-Werke Jun 1981 A
4289132 Rieman Sep 1981 A
4312364 Convert et al. Jan 1982 A
4314560 Helfgott Feb 1982 A
D263872 Rakocy et al. Apr 1982 S
4334539 Childs et al. Jun 1982 A
4346416 Riggle et al. Aug 1982 A
4378801 Oosten Apr 1983 A
4438766 Bowers Mar 1984 A
4463759 Garito Aug 1984 A
4473075 Rexroth Sep 1984 A
4476862 Pao Oct 1984 A
4492231 Auth Jan 1985 A
4517975 Garito May 1985 A
4550727 Rexroth May 1985 A
4541440 Parsonnet Sep 1985 A
4548207 Reimels Oct 1985 A
D281721 Scanlan Dec 1985 S
4557272 Carr Dec 1985 A
4565200 Cosman Jan 1986 A
4658815 Farin et al. Apr 1987 A
4658819 Harris Apr 1987 A
4658820 Klicek Apr 1987 A
4688569 Rabinowitz Aug 1987 A
4701193 Robertson et al. Oct 1987 A
4706667 Roos Nov 1987 A
4711239 Sorochenko et al. Dec 1987 A
4712544 Ensslin Dec 1987 A
4716897 Noguchi et al. Jan 1988 A
4754754 Garito Jul 1988 A
4821717 Wehrli Apr 1989 A
4827927 Newton May 1989 A
4834095 Miller May 1989 A
4886060 Wiksell Dec 1989 A
4892105 Prass Jan 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4962766 Herzon Oct 1990 A
4986839 Wertz et al. Jan 1991 A
5035695 Weber Jul 1991 A
D320271 Jones Sep 1991 S
5047026 Rydell Sep 1991 A
5047029 Aebi et al. Sep 1991 A
D320856 Scheller Oct 1991 S
D321056 Chambers Oct 1991 S
5067953 Feucht Nov 1991 A
D322483 Kishimoto Dec 1991 S
D322676 Chambers Dec 1991 S
5078716 Doll Jan 1992 A
5098430 Fleenor Mar 1992 A
5125058 Tenerez et al. Jun 1992 A
5127460 Abadi et al. Jul 1992 A
D329718 Sulik Sep 1992 S
5160334 Billings et al. Nov 1992 A
5186714 Boudreault et al. Feb 1993 A
5195959 Smith Mar 1993 A
5196007 Ellman Mar 1993 A
5217458 Parins Jun 1993 A
5217460 Knoepfler Jun 1993 A
5261905 Doresey Jun 1993 A
5224947 Cooper Jul 1993 A
5226939 Nicolas et al. Jul 1993 A
5243812 Strobel et al. Sep 1993 A
5246440 Van Noord Sep 1993 A
5267994 Gentelia et al. Dec 1993 A
5267998 Hagen Dec 1993 A
5275151 Shockey et al. Jan 1994 A
5281218 Imran Jan 1994 A
5290283 Suda Mar 1994 A
5304183 Gourlay et al. Apr 1994 A
D346866 Lotuaco May 1994 S
5318563 Malis et al. Jun 1994 A
5324288 Billings et al. Jun 1994 A
5325288 Satou Jun 1994 A
5342349 Kaufman Aug 1994 A
5342356 Ellman Aug 1994 A
D351227 Patton et al. Oct 1994 S
D352350 Rambo et al. Nov 1994 S
5336218 Linhares Nov 1994 A
5360428 Hutchinson Nov 1994 A
5364393 Auth et al. Nov 1994 A
5368560 Rambo et al. Nov 1994 A
5374188 Frank et al. Dec 1994 A
5380245 Reiterman et al. Jan 1995 A
5383923 Webster, Jr. Jan 1995 A
5396893 Oberg Mar 1995 A
5403311 Abele et al. Apr 1995 A
5413574 Fugo May 1995 A
5423779 Shimo et al. Jul 1995 A
5437664 Cohen et al. Aug 1995 A
5441499 Fritzsch Aug 1995 A
5456683 Fritzsch et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5456248 Fuji Nov 1995 A
5465248 Fuji Nov 1995 A
5478303 Foley-Nolen Dec 1995 A
5505728 Ellman Apr 1996 A
5514131 Edwards May 1996 A
5562503 Ellman Oct 1996 A
5571101 Ellman et al. Nov 1996 A
D376423 Monea Dec 1996 S
5594686 Hazen et al. Jan 1997 A
5599347 Hart et al. Feb 1997 A
5613966 Makower et al. Mar 1997 A
5620441 Gref et al. Apr 1997 A
5636733 Marchwiak Jun 1997 A
D382342 Rosen Aug 1997 S
5662680 Desai Sep 1997 A
5679401 Bawden Oct 1997 A
5683387 Garito Nov 1997 A
5685878 Falwell et al. Nov 1997 A
D388170 Sjostrom Dec 1997 S
5709675 Williams Jan 1998 A
5713942 Stern et al. Feb 1998 A
D393067 Geary et al. Mar 1998 S
5733282 Ellman et al. Mar 1998 A
D393715 Strickland Apr 1998 S
5735846 Panescu et al. Apr 1998 A
5741250 Garito Apr 1998 A
5746746 Garito May 1998 A
5755716 Garito May 1998 A
5766171 Silvestrini Jun 1998 A
5769702 Hanson Jun 1998 A
5807392 Eggers Sep 1998 A
5814044 Hooven Sep 1998 A
5833689 Long Nov 1998 A
5836897 Sakurai et al. Nov 1998 A
D402030 Roberts et al. Dec 1998 S
5871524 Knowlton Feb 1999 A
5891142 Eggers Apr 1999 A
D409335 Slater May 1999 S
5916158 Webster, Jr. Jun 1999 A
5924206 Cote et al. Jul 1999 A
5925039 Landingham Jul 1999 A
5948009 Tu Sep 1999 A
5954686 Garito Sep 1999 A
5984918 Garito Nov 1999 A
5993447 Blewett et al. Nov 1999 A
D417371 Searle et al. Dec 1999 S
5997533 Kuhns Dec 1999 A
5997733 Wilbur et al. Dec 1999 A
6001077 Ellman Dec 1999 A
6006755 Edwards Dec 1999 A
6010500 Sherman et al. Jan 2000 A
6039734 Goble Mar 2000 A
6044846 Edwards Apr 2000 A
6050993 Tu et al. Apr 2000 A
6059734 Yoon May 2000 A
6063085 Tay et al. May 2000 A
6068628 Fanton et al. May 2000 A
6080152 Nardella et al. Jun 2000 A
D428146 Svanberg et al. Jul 2000 S
6093186 Goble Jul 2000 A
D422024 Amdrews et al. Aug 2000 S
6102046 Weinstein et al. Aug 2000 A
6113596 Hooven et al. Sep 2000 A
6123702 Swanson et al. Sep 2000 A
D431972 Naft et al. Oct 2000 S
6156032 Lennox Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6203762 Skalla et al. Mar 2001 B1
6206842 Tu Mar 2001 B1
D441007 Garito et al. Apr 2001 S
D441077 Garito et al. Apr 2001 S
6214003 Morgan et al. Apr 2001 B1
6228078 Eggers et al. May 2001 B1
6228084 Kirwan, Jr. May 2001 B1
6231571 Ellman May 2001 B1
6235027 Herzon May 2001 B1
6238388 Ellman et al. May 2001 B1
6238394 Garito May 2001 B1
6245068 Olson et al. Jun 2001 B1
6251110 Wampler Jun 2001 B1
6280441 Ryan Aug 2001 B1
6296637 Thorne et al. Oct 2001 B1
6312428 Eggers et al. Nov 2001 B1
D453222 Garito Jan 2002 S
6348051 Farin et al. Feb 2002 B1
6355032 Hovda et al. Mar 2002 B1
6368324 Dinger et al. Apr 2002 B1
6387092 Burnside et al. May 2002 B1
6387093 Ellman et al. May 2002 B1
6395001 Ellman et al. May 2002 B1
6402742 Blewet et al. Jun 2002 B1
6409726 Ellman Jul 2002 B1
6413255 Stern Jul 2002 B1
6416512 Ellman et al. Jul 2002 B1
6417532 Tsunoda et al. Jul 2002 B2
6432105 Ellman Aug 2002 B1
6447509 Bonnet et al. Sep 2002 B1
6461352 Morgan et al. Oct 2002 B2
6506267 Fujiyasu et al. Jan 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6530924 Ellman Mar 2003 B1
6540745 Fairbourn et al. Apr 2003 B1
6544210 Trudel et al. Apr 2003 B1
6546935 Hooven Apr 2003 B2
6562032 Ellman May 2003 B1
6562036 Ellman May 2003 B1
6565561 Goble et al. May 2003 B1
6572613 Ellman et al. Jun 2003 B1
6582427 Goble Jun 2003 B1
6585791 Garito et al. Jul 2003 B1
6592580 Stockert Jul 2003 B1
6605080 Altshuler et al. Aug 2003 B1
6607528 Quick et al. Aug 2003 B1
6613047 Edwards Sep 2003 B2
6613048 Mulier et al. Sep 2003 B2
D481841 Hsu Nov 2003 S
6652514 Ellman Nov 2003 B2
6663620 Altshuler et al. Dec 2003 B2
6673072 Garito et al. Jan 2004 B1
6679881 Bybee Jan 2004 B1
6689071 Burbank et al. Feb 2004 B2
6730323 Murley et al. May 2004 B1
6749608 Garito Jun 2004 B2
6759624 Knowlton Jun 2004 B2
6766202 Underwood et al. Jul 2004 B2
6767348 Nakada et al. Jul 2004 B2
D494270 Reschke Aug 2004 S
6802842 Ellman Oct 2004 B2
D500168 Ho Dec 2004 S
6830569 Thompson et al. Dec 2004 B2
D500854 Eichel Jan 2005 S
6837884 Woloszko Jan 2005 B2
6892580 Pankey et al. May 2005 B2
6920883 Bessette et al. Jul 2005 B2
6926717 Garito Aug 2005 B1
D510138 Kim Sep 2005 S
D510158 Cheung Sep 2005 S
6974451 Altshuler et al. Dec 2005 B2
6976985 Altshuler et al. Dec 2005 B2
6994707 Ellman Feb 2006 B2
7070604 Garito Jul 2006 B1
7090649 Kang Aug 2006 B2
7094231 Ellman et al. Aug 2006 B1
D533943 Chen Dec 2006 S
7147634 Nesbitt Dec 2006 B2
D535397 Chen Jan 2007 S
7156844 Reschke et al. Jan 2007 B2
7160295 Garito Jan 2007 B1
7163336 Blakeley, III Jan 2007 B2
D538936 Bohmel et al. Mar 2007 S
D548843 Kertz Aug 2007 S
7258689 Russell Aug 2007 B2
7276058 Altshuler et al. Oct 2007 B2
D555803 Garito Nov 2007 S
7351252 Altshuler et al. Apr 2008 B2
7422586 Morris et al. Sep 2008 B2
7427289 Sierra et al. Sep 2008 B2
7473251 Knowlton et al. Jan 2009 B2
7479140 Ellman Jan 2009 B2
7507232 Garito Mar 2009 B1
D591365 Pasko et al. Apr 2009 S
7572251 Davison Aug 2009 B1
D601803 Reishus et al. Oct 2009 S
D609817 Piller et al. Feb 2010 S
D612510 Byle Mar 2010 S
7674261 Garito et al. Mar 2010 B2
7749218 Pellegrino et al. Jul 2010 B2
7763016 Altshuler et al. Jul 2010 B2
D625412 Garito Oct 2010 S
D628304 Aulwes et al. Nov 2010 S
7828794 Sartor Nov 2010 B2
7875026 Garito Jan 2011 B1
7879032 Garito et al. Feb 2011 B1
7879033 Sartor et al. Feb 2011 B2
7935110 Garito May 2011 B1
7947037 Garito May 2011 B1
7955327 Sartor et al. Jun 2011 B2
7959633 Sartor et al. Jun 2011 B2
7975702 Cho et al. Jul 2011 B2
8002768 Altshuler et al. Aug 2011 B1
8016824 Buchman, II et al. Sep 2011 B2
D646487 Leppla et al. Oct 2011 S
D652524 Messner Jan 2012 S
8100898 Gregg Jan 2012 B2
8100902 Sartor Jan 2012 B2
8113209 Masotti et al. Feb 2012 B2
8128622 Podhajsky et al. Mar 2012 B2
8162937 Cunningham et al. Apr 2012 B2
D660448 Lum et al. May 2012 S
8172835 Leyh et al. May 2012 B2
8190243 Welches et al. May 2012 B2
8231620 Mathonnet Jul 2012 B2
8235987 Craig Aug 2012 B2
8251989 Newton et al. Aug 2012 B1
8317782 Ellman et al. Nov 2012 B1
8321031 Ellman et al. Nov 2012 B1
8359104 Epstein Jan 2013 B2
D675829 Jakubow Feb 2013 S
D679502 Itano et al. Apr 2013 S
8449540 Sartor et al. May 2013 B2
8454591 Leyh et al. Jun 2013 B2
8460289 Sartor Jun 2013 B2
8506565 DeCarlo Aug 2013 B2
8540705 Mehta Sep 2013 B2
8591509 Fry et al. Nov 2013 B2
8597292 Kerr Dec 2013 B2
8608737 Mehta Dec 2013 B2
8632536 Kerr et al. Jan 2014 B2
8636733 Heard Jan 2014 B2
D698921 Koennecke et al. Feb 2014 S
8663216 Davison et al. Mar 2014 B2
8663218 Heard et al. Mar 2014 B2
8663219 Heard et al. Mar 2014 B2
8668688 Rusin Mar 2014 B2
D713150 Maurin et al. Sep 2014 S
8845630 Mehta et al. Sep 2014 B2
8915948 Altshuler et al. Dec 2014 B2
8945124 Craig Feb 2015 B2
8961511 Parmer Feb 2015 B2
8998891 Garito Apr 2015 B2
D728242 Kim et al. May 2015 S
D732164 Woloszko et al. Jun 2015 S
D733290 Burton et al. Jun 2015 S
D736462 Hendler et al. Aug 2015 S
9132058 Imboden et al. Sep 2015 B2
D742647 Hosier et al. Nov 2015 S
9271785 Parmer et al. Mar 2016 B2
D757953 Philips May 2016 S
9345531 Furnish May 2016 B2
9415235 Galen et al. Aug 2016 B2
D767897 Hosier et al. Oct 2016 S
D773676 Gufler Dec 2016 S
D793186 Tinius Aug 2017 S
D805781 Szymanski et al. Dec 2017 S
D809139 Marsot et al. Jan 2018 S
D821759 Szymanski et al. Jul 2018 S
D823478 Park Jul 2018 S
D830700 Xue Oct 2018 S
D831905 Benacquisto et al. Oct 2018 S
D835845 Graves et al. Dec 2018 S
10143831 Juergens et al. Dec 2018 B2
D837395 Gan Jan 2019 S
D839601 Fang Feb 2019 S
D840547 Harle et al. Feb 2019 S
D842491 Fleming et al. Mar 2019 S
D848677 Thalmann May 2019 S
D860441 Spycher et al. Sep 2019 S
D863574 Yan et al. Oct 2019 S
D863580 Lee Oct 2019 S
D864407 Zhou Oct 2019 S
D870294 Bechtel et al. Dec 2019 S
D870304 Du Dec 2019 S
10518097 Grez Dec 2019 B2
D873569 Nichols Jan 2020 S
D883675 Wong et al. May 2020 S
D884203 Segev May 2020 S
D892322 Yang Aug 2020 S
D901034 Zhang et al. Nov 2020 S
D902403 Marsot et al. Nov 2020 S
D905237 Knieriem et al. Dec 2020 S
D905238 Englert et al. Dec 2020 S
D905239 Englert et al. Dec 2020 S
D913483 Boschetti Sacco Mar 2021 S
D919814 Zikria et al. May 2021 S
20010018606 Ingle et al. Aug 2001 A1
20020029036 Goble Mar 2002 A1
20020032439 Hareyama Mar 2002 A1
20020077626 Ellman Jun 2002 A1
20020115991 Edwards Aug 2002 A1
20020133149 Bessette Sep 2002 A1
20020188284 To Dec 2002 A1
20030009165 Edwards Jan 2003 A1
20030050634 Ellman Mar 2003 A1
20030112204 Petterson Jun 2003 A1
20030130653 Sixto, Jr. et al. Jul 2003 A1
20030130711 Pearson Jul 2003 A1
20030139741 Goble Jul 2003 A1
20030139753 Wang Jul 2003 A1
20030153906 Sharkey et al. Aug 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030159700 Laufer Aug 2003 A1
20030163178 Davison Aug 2003 A1
20030216725 Woloszko Nov 2003 A1
20030216727 Long Nov 2003 A1
20030216728 Stern et al. Nov 2003 A1
20030233037 Bencini Dec 2003 A1
20030236487 Knownlton Dec 2003 A1
20040002443 Acharya et al. Jan 2004 A1
20040002705 Knowlton Jan 2004 A1
20040006339 Underwood Jan 2004 A1
20040030329 Hagg Feb 2004 A1
20040049251 Knowlton Mar 2004 A1
20040054365 Goble Mar 2004 A1
20040064175 Lessar Apr 2004 A1
20040111087 Stern Jun 2004 A1
20040116979 Truckai Jun 2004 A1
20040167516 Cucin Aug 2004 A1
20040181213 Gondo Sep 2004 A1
20040186535 Knowlton Sep 2004 A1
20040210214 Knownlton Oct 2004 A1
20040236203 Francesco Nov 2004 A1
20050004564 Wham Jan 2005 A1
20050027235 Knudsen et al. Feb 2005 A1
20050059889 Mayer Mar 2005 A1
20050090816 McClurken Apr 2005 A1
20050137662 Morris et al. Jun 2005 A1
20050154385 Heim Jul 2005 A1
20050256524 Long Nov 2005 A1
20050267465 Hillier et al. Dec 2005 A1
20060009763 Goble et al. Jan 2006 A1
20060052847 Davenport et al. Mar 2006 A1
20060173518 Kreindel Aug 2006 A1
20060009757 Long Oct 2006 A1
20060259102 Slatkine Nov 2006 A1
20070005053 Dando Jan 2007 A1
20070233191 Parmer Feb 2007 A1
20070055226 Garito Mar 2007 A1
20070083247 Wyeth et al. Apr 2007 A1
20070088413 Weber et al. Apr 2007 A1
20070093804 Kaveckis et al. Apr 2007 A1
20070093805 Auth et al. Apr 2007 A1
20070106349 Karni May 2007 A1
20070112342 Pearson et al. May 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070213700 Davison et al. Sep 2007 A1
20070213792 Yarosalvsky et al. Sep 2007 A1
20070282318 Spooner Dec 2007 A1
20080004678 Kreindel Jan 2008 A1
20080009849 Goble et al. Jan 2008 A1
20080051777 Haemmerich Feb 2008 A1
20080058796 O'Brien et al. Mar 2008 A1
20080091184 Knopp et al. Apr 2008 A1
20080091185 McGill et al. Apr 2008 A1
20080119846 Rioux May 2008 A1
20080125775 Morris May 2008 A1
20080183251 Azar et al. Jul 2008 A1
20080262490 Williams Oct 2008 A1
20080312651 Pope et al. Dec 2008 A1
20090012511 Welches et al. Jan 2009 A1
20090018531 Welches et al. Jan 2009 A1
20090024192 Mulholland Jan 2009 A1
20090036958 Metha Feb 2009 A1
20090054956 Sierra et al. Feb 2009 A1
20090062786 Garito et al. Mar 2009 A1
20090093864 Anderson Apr 2009 A1
20090112204 Aronow Apr 2009 A1
20090112205 McGill et al. Apr 2009 A1
20090138011 Epstein May 2009 A1
20090171341 Pope Jul 2009 A1
20090248004 Altshuler et al. Oct 2009 A1
20090248022 Falkenstein et al. Oct 2009 A1
20090306647 Leyh Dec 2009 A1
20090306648 Podhajsky Dec 2009 A1
20100023008 Heard Jan 2010 A1
20100030107 Hancock Feb 2010 A1
20100030212 Aramayo Feb 2010 A1
20100045427 Boone, III et al. Feb 2010 A1
20100049178 Deem Feb 2010 A1
20100114088 Buchman May 2010 A1
20100211060 Baron et al. Aug 2010 A1
20100217254 Mehta Aug 2010 A1
20100228243 Mehta Sep 2010 A1
20100228244 Hancock Sep 2010 A1
20100241116 Benamou Sep 2010 A1
20100249772 Mehta et al. Sep 2010 A1
20100262135 Berube Oct 2010 A1
20100312233 Furnish et al. Dec 2010 A1
20110046523 Altshuler et al. Feb 2011 A1
20110087215 Aldridge et al. Apr 2011 A1
20110087216 Aldridge et al. Apr 2011 A1
20110144729 Weber Jun 2011 A1
20110178584 Parmer et al. Jul 2011 A1
20110218464 Iger Sep 2011 A1
20110238056 Koss Sep 2011 A1
20110276046 Heimbecher Nov 2011 A1
20120022504 Epshtein Jan 2012 A1
20120022510 Welches et al. Jan 2012 A1
20120022512 Vaynberg Jan 2012 A1
20120095461 Herscher Apr 2012 A1
20120191072 Hancock Jul 2012 A1
20120265193 Lischinsky et al. Oct 2012 A1
20120265196 Turner Oct 2012 A1
20130006239 Pikramenos et al. Jan 2013 A1
20130245727 Kothare et al. Sep 2013 A1
20130245728 Galen et al. Sep 2013 A1
20130274841 Eckhous Oct 2013 A1
20130296835 Sierra et al. Nov 2013 A1
20140025033 Mirkov et al. Jan 2014 A1
20140182335 Lee et al. Jul 2014 A1
20140276768 Juergens Sep 2014 A1
20150005759 Welches et al. Jan 2015 A1
20150025526 Hua et al. Jan 2015 A1
20150094914 Abreu Apr 2015 A1
20150196351 Stone et al. Jul 2015 A1
20150297908 Alinsod et al. Oct 2015 A1
20150327926 Parmer Nov 2015 A1
20160135876 Parmer et al. May 2016 A1
20160256701 Furnish et al. Sep 2016 A1
20160263387 Alinsod et al. Sep 2016 A1
20160263388 Alinsod et al. Sep 2016 A1
20160263389 Alinsod et al. Sep 2016 A1
20160296278 Galen et al. Oct 2016 A1
20170071651 Allan et al. Mar 2017 A1
20170182334 Altshuler et al. Jun 2017 A1
20170182335 Altshuler et al. Jun 2017 A1
20170333249 Herchman, Jr. et al. Nov 2017 A1
20180001103 Alinsod et al. Jan 2018 A9
Foreign Referenced Citations (47)
Number Date Country
1697631 Nov 2005 CN
101610736 Dec 2009 CN
101905059 Dec 2010 CN
2011035 Oct 1970 DE
3627221 Feb 1988 DE
9102778 May 1991 DE
4423216 Aug 1995 DE
19850663 Mar 2001 DE
10138235 Jan 2003 DE
0368532 May 1990 EP
0423757 Apr 1991 EP
0480639 Apr 1992 EP
0332308 Sep 1998 EP
1707147 Oct 2006 EP
2258296 Dec 2010 EP
2742891 Jun 2014 EP
2790603 Oct 2014 EP
2967711 Jan 2016 EP
2154881 Sep 1985 GB
2490788 Nov 2012 GB
20154360005 Jun 2020 HK
S60180394 Sep 1985 JP
S63317073 Dec 1988 JP
H0795985 Apr 1995 JP
H07124101 May 1995 JP
H08168495 Jul 1996 JP
2006-271968 Oct 2006 JP
2001523513 Nov 2011 JP
2012254312 Dec 2012 JP
10-2017-0035486 Mar 2017 KR
9426228 Nov 1994 WO
1996022742 Aug 1996 WO
9634569 Nov 1996 WO
1996039088 Dec 1996 WO
1997015238 May 1997 WO
1998016162 Apr 1998 WO
1998038932 Sep 1998 WO
1999026546 Jun 1999 WO
2003103522 Dec 2003 WO
2004090939 Oct 2004 WO
2008012827 Jan 2008 WO
2008112931 Sep 2008 WO
2009031995 Mar 2009 WO
2009053117 Apr 2009 WO
2012052986 Apr 2012 WO
2013090528 Jun 2013 WO
2014145148 Sep 2014 WO
Non-Patent Literature Citations (53)
Entry
Examination Report in Australian Application No. 2019217623, dated Mar. 10, 2021, 4 pages.
Maximum Power Transfer Theorem—Electronics Hub. http://www.electronicshub.org/maximum-power-transfer-theorem/. Accessed Oct. 31, 2019.
Maximum Power Transfer Theorem in DC Theory, http://www.electronics-tutorials.ws/dccircuits/dcp_9.html. Accessed Oct. 31, 2019.
Zelickson, Brian D.,et al., “Histological and Ultrastrcutrual Evaluation of the Effects fo Radiofrequency-Based Nonablative Dermal Remodeling Device,” Arch Dermatol, Aug. 14, 2003, pp. 204-209, vol. 140, American Medical Association, United States.
Hantash, Basil M., et al., “Bipolar Fractional Radiofrequency Treatment Induces Neoelastogenesis and Neocollagenesis,” Lasers in Surgery and Medicine, Nov. 4, 2008, pp. 1-9, vol. 41, Wiley-Liss, Inc., United States.
Gonzalex-Suarez, Ana, et al., “Thermal and Elastic Response of Subcutaneous Tissue With Different Fibrous Septa Architectures to RF Heating: Numerical Study,” Lasers in Surgery and Medicine, Oct. 4, 2014, pp. 183-195, vol. 47, Wiley Periodicals, Inc., United States.
Kist, David, et al., “Ultrastructural Evaluation of Multiple Pass Low Energy Versus Single Pass High Energy Radio-Frequency Treatment,” Lasers in Surgery and Medicine, Jan. 5, 2006, pp. 150-154, vol. 38, Wiley-Liss, Inc., United States.
“The Effect of Heat on Collagen and Neocollagenesis,” Ultherapy.com, Jul. 20, 2011, 78 pages, available from http://www.ultherapy.com/uploads/document/professional/Effects-of-Temperature-on-Collagen.pdf. (last accessed May 9, 2018).
Abraham, Manoj T., et al. “Monopolar Radiofrequency Skin Tightening,” Facial Plastic Surgery Clinics of North America, 2007, pp. 169-177, vol. 15, Elsevier Inc.
Sadick, Neil, “Tissue Tightening Technologies: Fact or Fiction,” Aesthetic Surgery Journal, Dec. 11, 2007, pp. 180-188, vol. 28 No. 2, Sage Publications, United States.
Lauback, Hans J., et al., “Intense Focused Ultrasound: Evaluation of a New Treatment Modality for Precise Microcoagulation within the Skin,” American Society for Dermatologic Surgery, Inc., May 2008, pp. 727-734, vol. 34, Blackwell Publishing, United States.
White, W. Matthew, et al., “Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS),” Lasers in Surgery and Medicine, Dec. 27, 2007, pp. 67-75, vol. 40, Wiley-Liss, Inc., United States.
Hayashi, Kei, et al., “The Effect of Thermal Heating on the Length and Histologic Properties of the Glenohumeral Joint Capsule,” The American Journal of Sports Medicine, 1997, pp. 107-112, vol. 25 No. 1, Sage Publications, United States.
Vangsness Jr., C. Thomas, et al., “Collagen Shortening: An Experimental Approach with Heat,” Clinical Orthopedics and Related Research, Mar. 24, 1995, pp. 267-271, vol. 337, Lippincott-Raven Publishers.
Lin, Sung-Jan, et al., “Monitoring the Thermally Induced Structural Transitions of Collagen by Use of Second-Harmonic Generation Microscopy,” Optics Letters, Mar. 15, 2005, pp. 622-624, vol. 30 No. 6, Optical Society of America.
Paul, Malcolm, et al., “Three-Dimensional Radiofrequency Tissue Tightening: A Proposed Mechanism and Applications for Body Contouring,” Aesth Platic Surgery, Jul. 6, 2010, pp. 87-95, vol. 35., Springer.
Hayashi, Kei, et al., “Effect of Nonablative Laser Energy on the Joint Capsule: An in Vivo Rabbit Study Using a Holmium:YAG Laser,” Lasers in Surgery and Medicine, Feb. 21, 1996, pp. 164-171, vol. 20, Wiley-Liss, Inc., United States.
Invitation to Pay Additional Fees for PCT Application No. PCT/US2017/040585, dated Oct. 13, 2017, 23 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2017/040585, dated Dec. 6, 2017, 24 pages.
Third Party Submission in PCT Application No. PCT/US2017/040585, filed Jan. 29, 2018, 30 pages.
Third Party Submission in U.S. Appl. No. 15/640,710, filed Feb. 7, 2018, 58 pages.
International Search Report and Written Opinion of the International Searching Authority in PCT/US14/29862 dated Oct. 23, 2014.
Non-Final Office Action for U.S. Appl. No. 14/205,021, dated Jul. 28, 2016.
Office Action in Canadian Application No. 3,089,137, dated Aug. 11, 2021, 3 pages.
Fritzpatrick, et al. (2003). ‘Multicenter study of noninvasive radiofrequency for periorbilal tissue tightening’. Lasers in Surgery and Medicine 2003; 33:232-242. (11 page total).
Fritz, et al. (2004). ‘Radiofrequency treatment for middle and lower face laxity’. Arch Facial Plastic Surgery 2004; 6:370-373. (4 pages total).
Kushikata, et al., (2005). ‘Is topical anesthesia useful in noninvasive skin tightening using radiofrequency?’ J. Dermatologic Surgery 2005; 31:526-533. (8 page total).
Brunelle et al, A Bipolar Electrode for Vascular Electrocoagulation with Alternating Current. Radiology, vol. 137, No. 1, pp. 239 240, Oct. 1980.
Extended European Search Report dated Nov. 4, 2016 in European Application No. 14762910.9.
Non-Final Office Action for U.S. Appl. No. 14/214,627, dated Aug. 19, 2016, 16 pages.
Final Office Action for U.S. Appl. No. 14/214,627, dated Mar. 8, 2017, 21 pages.
Non-Final Office Action for U.S. Appl. No. 14/214,627, dated Jul. 14, 2017, 22 pages.
Final Office Action for U.S. Appl. No. 14/214,627, dated Oct. 31, 2018, 26 pages.
Non-Final Office Action for U.S. Appl. No. 14/214,627, dated May 25, 2018, 23 pages.
Final Office Action for U.S. Appl. No. 14/214,627, dated Sep. 21, 2018, 24 pages.
Non-Final Office Action for U.S. Appl. No. 14/214,627, dated Apr. 10, 2019, 19 pages.
Non-Final Office Action in U.S. Appl. No. 16/269,314, dated Feb. 14, 2022, 28 pages.
Restriction Requirement in U.S. Appl. No. 16/269,314, dated Jul. 29, 2021, 8 pages.
Third Examination Report in Australian Application No. 2019217623, dated Sep. 21, 2021, 4 pages.
Extended European Search Report in European Application No. 19750304, dated Oct. 21, 2021, 6 pages.
Chinese-language Office Action (with English-language translation provided) dated Jul. 12, 2012, issued by China's State Intellectual Property Office in Chinese Application No. 201010201340.2, 4 pages.
European Search Report for European Application No. 10164893, dated Oct. 11, 2010, 6 pages.
European Search Report dated Jan. 23, 2009 for European Patent application No. 08252879.5; 9 pages.
Office Action for Japanese Application No. 2008-218931, dated Feb. 5, 2013, 4 pages.
Notice of Reasons for Refusal for Japanese Application No. 2008-218931, dated Aug. 5, 2013, 6 pages.
European Search Report for European Application No. 10176756.4, dated Dec. 28, 2010, 5 pages.
European Search Report for European Application No. 99303449, dated Oct. 6, 1999, 3 pages.
International Search Report and Written Opinion in PCT Application No. PCT/US2019/016883, dated Jun. 24, 2019, 12 pages.
Extended European Search Report dated Nov. 8, 2016 in European Patent Application No. 14768330.4.
International Search Report and Written Opinion for PCT Application No. PCT/US2014/029862, dated Oct. 23, 2014.
Examination Report in Australian Application No. 2019217623, dated Oct. 27, 2020, 5 pages.
Restriction Requirement for U.S. Appl. No. 29/698,791, dated Mar. 29, 2022, 11 pages.
Office Action in Korean Application No. 10-2020-7025344, dated Mar. 29, 2022, 10 pages.
Related Publications (1)
Number Date Country
20200093533 A1 Mar 2020 US
Provisional Applications (1)
Number Date Country
61794732 Mar 2013 US
Continuations (1)
Number Date Country
Parent 14214627 Mar 2014 US
Child 16684937 US